Narvitas Medical Devices International Limited Signs Exclusive Distribution with Kebomed NL BV

Press Release ( - LONDON - Jul 28, 2016 - Narvitas Medical Devices Limited (Narvitas), a UK-based international medical device company, today announced the signing of an exclusive distribution agreement with Kebomed NL BV to sell and market the proprietary LapDome laparoscopic access device designed and manufactured by Narvitas. LapDome is the first CE-marked medical device designed to facilitate a reduction in laparoscopic surgery access complications and reduce access time.

Kebomed NL BV is a leading distributor of surgical devices in the Benelux market and is part of the pan-European Kebomed Group headquartered in Glostrup, Denmark.

“The receptivity to LapDome by Key Opinion Leaders in the surgical community in our beta markets of the United Kingdom and Benelux has been outstanding,” quoted Phillip Stubs, President of Narvitas Europe & Middle East. “Now that we have built clinical credibility with our platform and created traction with our initial accounts it is time to apply the market knowledge and strength of the Kebomed organization to drive market penetration.”

About LapDome® Laparoscopic Access Device

LapDome addresses a critical need in the laparoscopic surgical market (one of the largest medical procedure markets) and was developed to advance the standard of care for laparoscopic access. The LapDome device is a proprietary laparoscopic surgical access device. The device is a dome-shaped technology that utilizes negative pressure to raise the anterior abdominal wall for rapid and safe access of the abdomen by surgical instruments.

Source : Narvitas Medical Devices International Limited

You may also like this  


Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Already have an account ? Login

Reset Password

Already have an account ? Login


If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.